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Abstract
Background: The antimalarial activity and lipid profiles of  Methyl Jasmonate (MJ) were investigated against established 
malaria infection in vivo using BALB/c mice. 
Methods: Arteether (AE) and chloroquine (CQ) were used as reference drugs while ethanol was used as the vehicle for drug 
delivery for MJ. 
Results: Mice treated with 10 and 25 mg/kg MJ showed a remarkable reduction in percentage parasitemia by 68.3% and 
78.2% on day 10(post treatment) respectively while 45.4% and 87.2% reduction in percentage parasitemia were observed 
in the group treated with 50 mg/kg on day 3 and 10 ( post treatment ) respectively. The highest mean survival time was ob-
served in CQ followed by AE and MJ in dose-dependent manner. A progressive decrease in packed cell volume (PCV) was 
observed in infected untreated mice which led to the death of  all the mice by day 9 (post treatment). Infected mice treated 
with MJ showed reduced level of  HDL and LDL compared with infected untreated group. As the dose of  MJ increased in 
infected mice cholesterol levels increased while there was reduction in triglyceride. 
Conclusion: Overall there was marked decrease in parasitemia in Plasmodium berghei infected mice treated with graded 
doses of  MJ but appears to have reduced antimalarial activity compared with CQ and AE.
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Introduction 
Malaria is a major threat to public health and economic 
development in Africa .Current estimates indicate that 
at least one million children die of  malaria each year in 
Africa alone.1 Efforts at eradicating malaria have failed 
as parasite resistance to the most commonly used and 
affordable antimalarial drugs are developing rapidly.1 
There is need for discovery of   new drugs for the treat-
ment of   P. falciparum malaria which  should be effica-
cious against drug-resistant strains, provide cure within 
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a reasonable time (ideally three days or less) safe , suita-
ble for children and pregnant women, have appropriate 
formulations for oral use and above all, be affordable.2 
As part of  the effort at discovering new antimalarial 
agents, we evaluated on Methyl Jasmonate, a plant hor-
mone for its therapeutic effect. Methyl jasmonate has 
been known since 1962 as a fragrant component in the 
essential oil from flowers of  jasmine, Jasminium grandif-
lorum.3 The result of  an in vitro study demonstrated the 
antiparasitic potential of  Jasmonates using two major 
human blood parasites, Plasmodium falciparum and Schis-
tosma mansoni.4 Other studies also showed that Methyl 
Jasmonate (MJ) exhibited anticancer activity in vitro and 
in vivo.5-7
In this study, we evaluated possible in vivo antimalarial 
activity of  MJ and its effect on lipid profiles in mice 
infected with Plasmodium berghei.
Materials 
Chemicals
Methyl Jasmonate (MJ) was obtained from SERVA 
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(Herdelberg). It was dissolved in 95% ethanol. Chlo-
roquine and artheether were obtained from Laborate 
Pharmaceutical (India) and IPCA (India) respectively. 
Triglyceride and cholesterol kits were obtained from 
Vital Diagnostic Spb Ltd, Russia, HDL-cholesterol kit 
was obtained from Randox Laboratories Ltd United 
Kingdom while alanine aminotransaminase (ALT), as-
partate aminotransaminase (AST), and alkaline phos-
phatase (ALP) kits were obtained from Vital Diagnostic 
Spb Ltd, Russia.  All other reagents were of  analytical 
grade and purest quality available.
Method
Animals and parasite
Seventy BALB/c mice were obtained from the animal 
house of  the Institute of  Advanced Medical Research 
and Training (IAMRAT), College of  Medicine, Univer-
sity of  Ibadan, Nigeria. The animals were housed in 
group of  seven mice per cage, fed with standard mouse 
cubes (Ladokun feeds, Nigeria, Ltd) and supplied with 
clean drinking water ad libitum. P. berghei NK 65 (chlo-
roquine sensitive) used in this study was a donation 
to the laboratory of  one of  us (AOG) by Malaria Re-
search and Reference Reagent Resource centre (MR4) 
USA. The parasites were maintained in animals by serial 
blood passages in mice. 
Study of  the course of  infection and antimalarial 
activity
The course of  infection following intraperitoneal in-
oculation of  mice was studied in each experimental 
mouse that received 1×107 parasitized red blood cells 
in 0.2ml inoculums. Thin films were made from the tail 
vein of  infected mice, fixed with methanol and stained 
with 10% Giemsa stain using standard procedure. Par-
asitemia was monitored daily and screened under X 
1000 magnification using a light microscope. Treatment 
commenced when parasitemia was established (about 
10%). In vivo antimalarial activity against P. berghei infec-
tion in mice was monitored according to Rane’s test as 
described by Elufioye et al..8 The Rane’s test relies on the 
ability of  standard inoculum of  P. berghei to kill the re-
cipient mouse within 12 days of  inoculation. Extension 
of  survival beyond 12 days is regarded as activity.
Study design
Mice weighing between 18 and 30g were distributed 
into 10 groups of  seven animals each. Four groups of  
animals were uninfected; one group received the vehicle 
only (0.3ml ethanol) and served as normal uninfected 
control group, while the three other uninfected groups 
received 10, 25 and 50 mg/kg body weight MJ respec-
tively once daily for four consecutive days. Six groups 
were infected with Plasmodium berghei (NK 65 strain); 
one group was not treated while the remaining five 
groups were treated with 3 mg/kg arteether (AE), 10 
mg/kg chloroquine (CQ), and MJ 10, 25 and 50 mg/
kg body weight respectively. The groups that received 
AE and CQ were administered standard doses for three 
consecutive days while those groups that received MJ 
were treated for four consecutive days after infection 
was established. All administration was by oral gavage. 
Thin films were made from the blood collected from 
the tail of  infected mice for the first 7 days to determine 
the percentage parasitemia. Films were made weekly for 
28 days. The mice were sacrificed 24 hours after the 
administration of  the last treatment (D4). All the pro-
cedures and the protocol conformed to the guidelines 
of  the National Institute of  Health (NIH) publication 
85-23, 1985) for laboratory animal care and use. Two 
milliliter of  blood was collected into plain bottles, cen-
trifuged for 10 minutes at 3,000g using bench centri-
fuge and serum were collected to determine ALT, AST, 
and ALP activities, total cholesterol, triglyceride and 
high density lipoprotein- cholesterol (HDL-Cholester-
ol) levels. Liver, kidney and brain tissues were collected 
into test tubes containing 10% formalin stored at 40C 
for histopathological examination. 
 
Biochemical assays
In vitro quantitative determination of  ALT, AST and 
ALP activities, total cholesterol and triglyceride levels 
in the serum were determined using Vital Diagnostics 
Spb Ltd kits while RANDOX Laboratories Ltd kit was 
used to determine high density lipoprotein- cholester-
ol (HDL-Cholesterol) level. The activities of  ALT and 
AST were determined using Kinetic UV method (IFCC 
modification).The method is based on change in spec-
tral absorption of  NADH when converted to NAD.
ALP activity was determined using End point method 
which is based on the formation of  p-nitrophenol af-
ter increase in spectral absorption. The p-nitrophenol 
formed was proportional to the alkaline phosphate ac-
tivity in the sample. Cholesterol level was determined by 
hydrolyses of  cholesterol esters to free cholesterol by 
cholesterol esterase and resulted to red quinoneimine 
production. Triglyceride level was assayed by the chro-
magen production which is directly proportional to 
concentration of  triglyceride. Supernatant fraction of  
cholesterol was used to determine HDL-cholesterol 
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using enzymatic method. LDL-cholesterol was deter-
mined using Friedewald’s formula.9
Statistical analysis
The results were expressed as mean ± standard devia-
tion (SD) of  seven mice per group. Data was analyzed 
by one-way analysis of  variance (ANOVA) followed by 
post hoc Duncan’s multiple range test using SPSS ver-
sion (15.0) statistical software. Level of  significant dif-
ferences was set at p<0.05.
Results
A progressive increase in percentage parasitemia was 
observed in infected untreated mice with maximum of  
177% increase by day 3 (post treatment) which led to 
the mice death. AE and CQ gave maximum response in 
parasitemia reduction on day 3 (post treatment) by 90% 
and 91.9% respectively while parasitemia reduction on 
day 3 (post treatment) in 50 mg MJ treated group was 
45.4%. The maximum percentage reduction in para-
sitemia was obtained on day10 (post treatment) with 
87.2%, 78.4% and 68.3% in 50, 25 and 10 mg/kg MJ 
treated groups respectively. Mean survival time for in-
fected untreated group was significantly reduced due to 
the P. berghei infection, while a doubling effect was ob-
served for AE, CQ and MJ treated groups when com-
pared with infected untreated group (Table 1),(Fig 1). 
 
Figure 1 Effect of treatment on percentage parasitaemia 
 
 
IU= infected - untreated animals, P + CQ =P berghei infected animals – treated with 10mg/kg  chloroquine, P + AE = P .berghei in-
fected animals – treated with 3mg/kg   arteether, P + MJ (10mg) = P. berghei infected animals – treated with 10mg/kg methyl jasmonate, 
P + MJ (25mg) = P .berghei infected animals – treated with 25mg/kg methyl jasmonate, P + MJ (50mg) = P. berghei infected animals 
– treated with 50mg/kg methyl jasmonate. Note that all animals in the infected untreated had died by day 10.
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Table 1: Mean survival time of infected treated and infected untreated animals 
 
Treatments Groups                                   Days 
Infected untreated (IU)                            9.3±4.9 
P + AE                                                          27.2±2.3 
P + CQ                                                          31.5±2.5 
P+ MJ (10mg)                                              21.6±3.4 
P+ MJ (25mg)                                              22.3±3.1 
P+ MJ (50mg)                                              22.6±2.9 
 
Values are reported as mean (n=7) 
IU = Infected-untreated animals, P + CQ = P.berghei  Infected animals – treated with 10mg/kg chloroquine, P + AE= 
P.berghei  infected animlas-treated with 3 mg/kg arteether, P + MJ (10mg)= P.berghei  infected animals-treated with 
10mg/kg methyl jasmonate, P + MJ (25mg)= P.berghei  infected animals- treated with 25mg/kg methi jasmonate, P + MJ 
(50mg) = P.berghei  infected animals-treated with 50mg/kg methiyl jasmonate. 
 
As expected a decrease in parked cell volume (PCV) 
was observed in infected untreated mice as percentage 
parasitemia increased. The PCV of  groups treated with 
AE and CQ were not reduced markedly when com-
pared with infected untreated and MJ treated groups. 
(Table 2)
ALT and AST activity in infected untreated group in-
creased relative to normal control (Fig 2). CQ and AE 
inhibited the increase caused by P. beghei infection while 
MJ on the other hand inhibited the increase in AST lev-
els but had no effect on ALT (Fig 2). 
 Table 2: Effect of MJ, AE, and CQ treatments on packed cell volume (PCV) in 
P. berghei infected and uninfected mice 




















































































































Values are reported as mean± S.D. (n=7) * =   Significant when compared with base line PCV on day 0  
Asterisk indicate, significant difference from infected untreated(p<0.05); IU= P. berghei infected - untreated animals, P + CQ = P. berghei infected animals – treated with 10mg/kg  chloroquine, P + 
AE = P. berghei infected animals – treated with 3mg/kg   arteether, P + MJ (10mg) = P. berghei  infected animals – treated with 10mg/kg methyl jasmonate, P + MJ (25mg) = P. berghei infected 
animals – treated with 25mg/kg methyl jasmonate, P + MJ (50mg) = P. berghei  infected animals – treated with 50mg/kg methyl jasmonate , control – administered with ethanol, M J(10mg), MJ 
(25mg) and MJ (50mg/kg) = uninfected animals administered with 10mg,25mg and 50mg/kg methyl jasmonate, day 7,8,9 and 10=post infection 
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Table 2: Effect of MJ, AE, and CQ treatments on packed cell volume (PCV) in P. berghei infected 
and uninfected  mice
 




 IU= P. berghei infected - untreated animals, P + CQ = P. berghei infected animals – treated with 10mg/kg  chloroquine, 
P + AE = P. berghei infected animals – treated with 3mg/kg   arteether, P + MJ (10mg) = P. berghei  infected animals – 
treated with 10mg/kg methyl jasmonate, P + MJ (25mg) = P. berghei infected animals – treated with 25mg/kg methyl 
jasmonate, P + MJ (50mg) = P. berghei infected animals – treated with 50mg/kg methyl jasmonate , control – 
administered with ethanol, M J(10mg), MJ (25mg) and MJ (50mg/kg) = uninfected animals administered with 
10mg,25mg and 50mg/kg methyl jasmonate 
It was observed that there was increase in ALT and 
AST activity in uninfected group administered with MJ 
relative to control(fig 2). Although there was elevation 
in ALT and AST in uninfected animals administered 
with MJ but the elevation was not significant (p >0.05) 
when compared with infected untreated animals rela-
tive to control (Fig 2). ALP in infected untreated group 
increased markedly compared with infected treated and 
control groups (Fig 3).
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Figure 3 Effect of treatment on ALP activity among various groups 
 
 
                                           
IU= P. berghei infected - untreated animals, P + CQ = P. berghei infected animals –treated with 10mg/kg  chloroquine, 
P + AE = P. berghei infected animals – treated with 3mg/kg   arteether, P + MJ (10mg) = P. berghei  infected animals – 
treated with 10mg/kg methyl jasmonate, P + MJ (25mg) = P. berghei infected animals – treated with 25mg/kg methyl 
jasmonate, P + MJ (50mg) = P. berghei  infected animals – treated with 50mg/kg methyl jasmonate , control – 
administered with ethanol, M J(10mg), MJ (25mg) and MJ (50mg/kg) = uninfected animals administered with 
10mg,25mg and 50mg/kg methyl jasmonate 
Infected untreated group had the highest level of  HDL 
and LDL compared with infected groups treated with 
either AE, CQ and MJ, uninfected and control group 
(Fig 4). An increase in HDL and LDL was observed 
in groups administered with MJ in both infected and 
uninfected animals relative to control (Fig 4). An in-
crease in cholesterol was observed in the groups treated 
with MJ compared with control but triglyceride levels 
were similar in MJ treated groups and control. Infected 
group treated with AE showed a significant increase (p 
<0.05) in cholesterol and triglyceride in comparison to 
control (Fig 4).
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Figure 4 Effect of treatment on lipid profiles in various groups 
 
 
 IU= P. berghei infected - untreated animals, P + CQ = P. berghei infected animals – treated with 10mg/kg  chloroquine, 
P + AE = P. berghei infected animals – treated with 3mg/kg   arteether, P + MJ (10mg) = P. berghei  infected animals – 
treated with 10mg/kg methyl jasmonate, P + MJ (25mg) = P. berghei infected animals – treated with 25mg/kg methyl 
jasmonate, P + MJ (50mg) = P. berghei  infected animals – treated with 50mg/kg methyl jasmonate , control – 
administered with ethanol, M J(10mg), MJ (25mg) and MJ (50mg/kg) = uninfected animals administered with 
10mg,25mg and 50mg/kg methyl jasmonate 
No significant changes in histology of  the brain was 
observed in all the groups relative to control.The kid-
ney of  treated and untreated mice were normal except 
for P. berghei infected mice treated with CQ that showed 
presence of  protein cast ( Fig 5{a}). 
Perivascular mononuclear cell infiltration occured in 
the liver of  all P. berghei infected mice treated  and un-
treated ( Fig 5{b}),while necrosis was observed in the 
liver of   infected untreated mice ( Fig 5{c}). 
Discussion
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Figure 5 (a) Effect of chloroquine treatment in kidney 
    
 The photomicrogragraph of the kidney  of mice passaged with P .berghei and treated with chloroquine 10mg/kg body 
weight showing protein casts (Arrow), (H&E Stain) 
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Figure 5 (b) Effect of methyl jasmonate (MJ) 25 mg/kg/body weight in liver 
The photomicrograph of the liver of mice passaged with Plasmodium berghei ,and treated with 25mg/kg  body weight 
MJ,showing perivascular mononuclear cell infiltration(arrow), (H&E Stain) 
 
Figure 5 (c) Effect of plasmodium berghei in the liver of untreated mice 
The photomicrogragraph of the liver of mice passaged with P.berghei ,without treatment, showing mononuclear cell 
infiltration and necrosis (arrow), (H&E Stain) 
Antimalarial drug resistance is a major public health 
problem, which hinders the control of  malaria. There is 
an urgent need to increase the armamentarium against 
malaria. As part of  this effort, we investigated the an-
timalarial activity of  Methyl Jasmonate in P. berghei in-
fected mice. Results of  our studies demonstrated that 
MJ exhibited a dose-dependent significant reduction 
in percentage parasitemia from day 3 (post treatment). 
MJ at a dosage of  50 mg/kg reduced parasitemia better 
than 10 and 25 mg/kg doses. However MJ was less ef-
fective when compared to CQ and AE for which con-
siderable reduction in parasitemia was observed by day 
2 (post treatment). There was however resurgence in 
parasitemia in AE treated mice on day 10 (post treat-
ment), which is in agreement with the recrudescence 
that occurrs to artemisinin monotherapy.10 
As the percentage parasitemia increased in infected 
untreated mice, the PCV as expected decreased mark-
edly until the mice died. This is consistent with previ-
ous studies.11 A decrease in PCV was observed in in-
fected mice treated with MJ relative to base line PCV 
before infection while the PCV obtained in uninfected 
mice administered with MJ were not affected. P. berghei 
caused significant increase in cholesterol and triglycer-
ide in infected untreated mice relative to control. Sim-
ilarly a significant increase in HDL-C and LDL-C was 
observed in infected untreated mice in comparison to 
infected treated and uninfected groups .This finding is 
in concordance with report of  Sherman et al.12 that rats 
infected with P. berghei had   elevated lipid profiles. 
A significant increase in HDL-C and LDL-C occurred 
in infected and uninfected mice administered with MJ 
relative to AE and CQ treated and control groups this 
may be related to the lipid nature of  MJ.13 Liver enzymes 
(ALT, AST and ALP) are used as markers of  liver func-
tion and can be used for drug safety evaluation.14,15 They 
are involved in intermediary metabolism and present in 
high concentration in the liver and are released rapidly 
into the plasma in cases of  acute destruction of  tissue 
as in myocardial infarction or hepatocellular necrosis.15 
This study demonstrated significantly high activity of  
ALT, AST and ALP in infected untreated group relative 
to control which is an indication of  hepatocellular func-
tion impairement.15 MJ inhibited the increase in AST 
and ALP level but had no effect on ALT in infected 
mice. The increase in ALT is the most sensitive marker 
for liver cell damage while AST and ALP elevation may 
be caused by other disease conditions apart from hepa-
tocellular damage.16 MJ treatment of  uninfected mice 
however caused elevation in ALT, AST and ALP com-
pared with control. 
The changes observed in ALT,AST and ALP levels 
among the uninfected mice might be due to the vehi-
cle used for Methyl Jasmonate (10% ethanol). Protein 
cast was observed in the kidney of  infected mice treated 
with CQ. Perivascular mononuclear cell infiltration was 
observed in the livers of  infected treated mice with CQ, 
MJ 25 and 50 mg/kg, while necrosis was observed in 
the livers of  untreated group. However, livers of  infect-
ed mice treated with AE were normal, which supports 
the report of  Edington17. Gilles et al.18 reported that 




It is concluded that MJ has appreciable antimalarial ac-
tivity in P. berghei infected mice although reduced rela-
tive to AE and CQ. Administration of  MJ in P. berghei 
infected and uninfected mice showed no significant 
toxicity in the brain, liver and kidney. MJ will be a good 
candidate for consideration as a new antimalarial agent. 
Further in vitro and in vivo evaluation and possible 
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